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Abstract. Managing the use of multiple medicines, also known as polypharmacy, 
is a challenge for physicians, pharmacists and patients alike, and is a particular 
concern for patients with multiple chronic conditions (aka multimorbidity). 
Patients with multimorbidity are often required to take a considerable number of 
medications for their different ongoing conditions, and managing/revising these 
medications effectively is a challenge. There is a need to periodically rearrange 
drugs taking into account patient's preferences and avoiding adverse drug reactions. 
We present an incremental, constraint solver based framework for a clinical 
decision support system that makes it possible to check drug prescriptions using 
information from multiple sources, including a constraint database and patient 
records. We illustrate how it can be used to manage clinical conditions while 
reducing polypharmacy problems and undesired side effects in a patient-centric 
approach.  
Keywords. Polypharmacy, multimorbidity, constraint solvers, clinical decision 
support systems 
1. Introduction 
Polypharmacy can be defined as the concomitant use of multiple medications by a 
patient [1] [2], and is commonly linked to the treatment of multiple chronic diseases, 
also known as multimorbidity, which occurs with the highest prevalence in the elderly 
[3]. In addition, the use of many drugs simultaneously to treat different diseases is not 
always clear and may not match patient expectations and preferences [3] [4]. It is 
important that the use of various medications is safe and effective [5], and this may 
become questionable when the risks of medication combinations outweigh the benefits. 
Studies have indicated that there are risks associated with the use of multiple 
medications, which include drug interactions and adverse drug reactions [6] [7].  Drug 
interactions have a negative outcome when the reaction between drugs has, for 
instance, a toxic effect or decreases the effect of one drug [6]. An adverse drug reaction 
is defined as any undesirable medical occurrence caused by a pharmaceutical product 
but not necessarily related to treatment [8] and may occur for different reasons, such as 
the wrong dose, drug or route [9].  Studies have shown that over half of the hospital 
admissions and between 25% to 50% of outpatient care arise from adverse drug 
reactions which could have been mitigated [10].  
The complexity of taking decisions when treating patients can be a significant 
challenge, especially in the presence of polypharmacy which invariably combine many 
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factors/variables. Additionally, treatments should be personalised and the patient's 
individual preferences included in the decision process. The position we take is that, 
specially in the case of complex decision making, automated tool support is essential. 
Our approach combines medical knowledge with formal methods techniques to search 
for and compute optimal solutions for managing the treatment of patients with complex 
needs. This paper is structured as follows: we describe the proposed framework in 
Section 2 and illustrate how our approach works in Section 3. We conclude the paper 
with some overall comments and future work in Section 4. 
2. Proposed Framework 
To support physicians in making appropriate decisions, we propose a clinical decision 
system framework to check and manage constraints between drugs, exams, and 
diseases and take into account patient preferences.  The solution consists of five parts: 
the Electronic Medical Record (EMR) interface, the Knowledge interface, the 
Knowledge database, the Inference engine and the Decision maker 
 
Figure 1. Multi-Source Decision Support System Framework. 
The framework shown in Figure 1 takes constraint data from the knowledge 
sources and patient data from the EMR which are processed independently. The 
information from both sources is used in the Inference engine, which is responsible for 
merging both patient and constraint data.  The Inference engine checks in the 
knowledge database if there are constraints that need to be solved according to the 
patient information then automatically searches for alternative solutions without 
constraints and displays them for the doctor to decide the appropriate prescription. 
2.1.  Knowledge interface and database 
There are different sources of constraints in knowledge sources which can be used in 
the Inference engine. To standardize the link between the Inference engine and its 
sources, we propose a generic knowledge interface. This interface enables the retrieval 
of data about different constraint types such as drug interactions, side effects, 
alternative drugs, exam and vital sign reference values. Developing a generic interface 
will allow users to connect new and different types of constraint sources.  
The knowledge interface operates in three steps: receive, process/convert and 
deliver. The data can be received from different channels. Each channel is for a specific 
type of constraint (e.g., for drug interaction data) and has a custom layout. The data 
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received by the hub is converted into a formal model illustrated in Figure 1 on the 
assert  text between the knowledge interface and database, which is compatible with 
the Z3 [11] solver. Delivery is divided into checking (searching the knowledge database 
to see if a specific constraint is already recorded) and inserting. If a constraint is 
already recorded it is discarded, otherwise the system inserts it in the knowledge 
database to be used by the Inference engine.  
2.2. EMR interface 
The EMR interface deals with different types of patient data to link the information 
between the EMR database and Inference engine. Initially, the EMR interface was 
developed to receive all available information from the patient such as Computerized 
Physician Order Entry (CPOE) which includes drug prescriptions, laboratory results 
from the Laboratory Information System (LIS), Vital Signs and Patient Records. The 
EMR interface also has a channel to receive information on patient preferences. For 
example, there are medications with side effects such as headache, dizziness or 
drowsiness, that patients may want to avoid. In these situations, physicians should 
select drugs which avoid particular side effects. 
Similar to the knowledge interface, after receiving information from the EMR, the 
EMR interface processes the data in three steps: identify, process/convert and deliver. 
In the first step, the hub identifies the type of data (e.g., exam results, drug 
prescriptions, vital signs or patient records). In the next step, the hub converts the data 
into a formal showed in Figure model to be compatible with the Z3 [11] solver, showed 
in Figure 1 between the EMR database and interface. Finally, the information is 
delivered to the Inference engine. 
2.3. Inference engine and decision maker 
The Inference engine was proposed to create links between the knowledge database and 
patient data, so that it is possible for example to search for drugs that do not have 
undesired side effects. The compiler receives patients’ clinical information and selects 
the related constraints on the knowledge database to define solutions using the 
constraint solver Z3 [11]. 
Firstly, the compiler receives the data from the EMR interface and checks if there 
are constraints that need to be solved. Secondly, after receiving patient data, a query is 
executed in the knowledge database based on the received data (e.g., Acetaminophen 
and Leflunomide drug prescription), to find the linked constraint (in this example, the 
drug-drug interaction, drug-adverse reaction, drug-disease interaction and drug-food 
interaction). Finally, if constraints are found for the patient data, the compiler is 
executed to solve or manage them. As a result, the compiler returns advice to 
physicians, the decision maker, which takes into account a number of important 
variables and allows the physician to choose the most appropriate treatment plan to be 
adopted for a given patient.  
3. Practical example 
To illustrate how our approach works, we present an extended hypothetical example 
taken from [5] about a 69 years old man. The patient arrives in hospital after a fainting 
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and seizures episode and complaining about arm pain and dizziness. The physician 
checks the patient’s previous data on the EMR as shown on the first row of Table 1. 
Thereafter the physician requests a blood glucose test, verifies the blood pressure and 
prescribes Dextrose 10% and Electrolyte 500 ml and Codeine phosphate (7,5 mg) + 
Acetaminophen (300 mg) as shown in the second row of Table 1.  
During the consultation, the patient data (previous and new records) is sent from 
the EMR to the EMR interface and sent to the Inference engine. 
 
Table 1. Patient data 
Current medical history Result exams Drugs Patient’ preferences 
(Previous) 
Frequent falls 
Dementia – mixed 
Alzheimer’s disease 
/alcohol abuse 
(Previous) 
BP 120/74 
mmHg 
Blood glucose 
test 90 mg/dL 
(Continuous use) 
Trazodone 150 mg 
Thiamine 50 mg 
Bendroflumethiazide 2.5 mg  
(Previous) 
Patient reports: 
feeling tired and short 
of breath 
(New records) 
Fainting episode, seizures 
(New records) 
BP 132/74 
mmHg 
Blood glucose 
test 125 mg/dL 
(New records) 
Codeine phosphate (7,5 mg) 
+ Acetaminophen (300 mg) 
Dextrose 10% and Electrolyte 
500 ml 
(New records) 
Patient reports:  
Feeling arm pain and 
dizziness 
Given the drug interactions and medical recommendations from the knowledge 
source, the Inference engine checks the constraints from the knowledge database 
against the patient data and highlights the relevant constraints as in the three tables 
below. 
 
Table 2. Constraint drug interaction data 
Drug Drug Interaction Severity 
Trazodone Codeine 
phosphate 
risk of a rare but serious condition called the serotonin 
syndrome, which may include symptoms such as 
confusion, hallucinations, seizures, blurred vision 
Moderate 
Trazodone Bendroflumethiazide lowering blood pressure Moderate 
 
Table 3. Medical recommendations 
Drug Condition Recommendation 
Dextrose 10%  blood glucose test 125 mg/dL May cause hyperglycemia 
 
Table 4. Side effects 
Drug Side effects Used for the following conditions (associated conditions) 
Trazodone 10%  dizziness Alcohol Dependence, Alzheimer's Disease (AD), Dementias 
Bendroflumethiazide dizziness High Blood Pressure 
Codeine dizziness Pain, Acute, Severe Pain, Moderate Pain 
 
Thereafter, the physician interactively manages these constraints with the 
Inference engine. To solve the first interaction in Table 2 between Trazodone and 
Codeine phosphate, the system shows to the physician the drug interaction and lists 
alternative drugs to manage the problem. The alternative drugs are selected from the 
knowledge database according to the associated conditions shown in Table 4. For all 
listed drugs, the system shows all the possible constraints, for example, interactions 
with other drugs or side effects that should be avoided according to patient preferences. 
The alternative drugs are sorted from the best to the more intricate options, that is, from 
the smallest to the biggest number of related constraints. The physician can also decide 
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to exclude a drug from the prescription or prescribe a drug that is not listed, for 
example, to minimise a side effect. 
Moreover, if the physician decides to change/include/exclude a drug, the system 
reloads in real-time the constraints based on this decision. Otherwise, the system keeps 
the existing constraints and flags the chosen drugs in order to avoid repeated alerts in 
case of reloading. The same process is repeated to solve the medical recommendations 
in Table 3 and the side effects in Table 4. The process ends when there are no 
constraints to be solved, which does not mean that all restrictions have been solved, but 
that all decisions regarding the constraints have been made. 
4. Conclusion 
In this paper, we presented the vision of a framework to support physicians to make the 
appropriate decisions considering different types of drug constraints and interactions, 
and respecting patient preferences. The framework is enabled to receive multiple data 
sources combining patient and constraint records. As a clinical decision support 
system, our proposed automated solution only offers advice and the final decision 
remains with the physician. We demonstrated how the system can give advice to 
manage drug conflicts for a realistic but hypothetical example, highlighting the 
importance of gathering medical evidence and knowledge in decision making. In future 
work, we intend to fully develop, implement and evaluate the proposed solution. 
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